Moses Kamya

Last updated
Moses R Kamya
Born1960 (age 62–63)
Uganda
NationalityUgandan
CitizenshipUganda
Alma mater Makerere University
(Bachelor of Medicine and Bachelor of Surgery)
(MMed in Internal Medicine)
University of California, Berkeley
(Master of Public Health)
University of Antwerp
(PhD in Biomedical Sciences)
Occupation(s) Physician and Academic
Years active1988 — present
TitleProfessor and Chair, Department Medicine, Makerere University
Spouse(Mrs Kamya)

Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences. [1] [2]

Contents

Background and education

Kamya was admitted to Makerere University School of Medicine in 1980, graduating in 1985, with a Bachelor of Medicine and Bachelor of Surgery. In 1988, he returned to the institution to study for the Master of Medicine (MMed) program. He graduated in 1991 with an MMed in Internal Medicine. He also holds a Master of Public Health in Epidemiology, awarded in 1995, by the University of California, Berkeley School of Public Health. His PhD in Biomedical Sciences was awarded by the University of Antwerp in 2007. [1]

Career

Professor Kamya's research and teaching in infectious diseases spans a period in excess of 20 years. He specifically has special interest in the interaction between malaria and HIV/AIDS. He serves as Professor and Chair (Head) of the Department of Medicine at Makerere University College of Health Sciences. He is also a key researcher and case manager in AIDS care at Mulago National Referral Hospital, the teaching hospital of the university, and at the adjacent Makerere University Infectious Diseases Institute. [1] [2]

His research spans HIV, malaria, tuberculosis, STDs. He trains medical students and residents in the design and execution of infectious diseases research. Among his many responsibilities, he also serves as editor of the Uganda antiretroviral therapy (ART) clinical guidelines. He is also the chair of the Uganda Ministry of Health adult ART management committee. He has published widely in peer journals and has contributed to several books on the subject matter, [1] [2]

Researcher

As an academic as well as a medical researcher, he has participated in research studies which has been published in respectable academic and scientific journals. Some of these among others include; Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. This study found significant cryptococcal meningitis associated mortality persists, despite the administration of amphotericin B and HIV therapy. [3] Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/μL who start HIV therapy in resource-limited settings. [4] HIV testing and treatment with the use of a community health approach in rural Africa. [5] Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. [6] Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. [7] Dihydroartemisinin–piperaquine for the prevention of Malaria in pregnancy. [8] Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. This study concluded that light traps provide an alternative method for sampling indoor-resting mosquitoes to human-landing catches and have the advantage that they protect individuals from being bitten during collection, are easy to use and are not subject to collector bias. [9] Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. [10] Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. [11] Factors determining the heterogeneity of Malaria incidence in children in Kampala, Uganda. [12] Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for treatment of malaria: A randomized trial. [13] COVID-19: Shining the Light on Africa. [14] Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. [15] and Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. [16]

See also

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Medical condition

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

<i>Plasmodium falciparum</i> Protozoan species of malaria parasite

Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. It is responsible for around 50% of all malaria cases. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.

<span class="mw-page-title-main">Artemisinin</span> Group of drugs used against malaria

Artemisinin and its semisynthetic derivatives are a group of drugs used in the treatment of malaria due to Plasmodium falciparum. It was discovered in 1972 by Tu Youyou, who shared the 2015 Nobel Prize in Physiology or Medicine for her discovery. Artemisinin-based combination therapies (ACTs) are now standard treatment worldwide for P. falciparum malaria as well as malaria due to other species of Plasmodium. Artemisinin is extracted from the plant Artemisia annua a herb employed in Chinese traditional medicine. A precursor compound can be produced using a genetically engineered yeast, which is much more efficient than using the plant.

<span class="mw-page-title-main">Cryptococcosis</span> Potentially fatal fungal disease

Cryptococcosis is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and brain, where it appears as a meningitis. Cough, difficulty breathing, chest pain and fever are seen when the lungs are infected. When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity and confusion or changes in behavior. It can also affect other parts of the body including skin, where it may appear as several fluid-filled nodules with dead tissue.

<span class="mw-page-title-main">Artemether</span> Chemical compound

Artemether is a medication used for the treatment of malaria. The injectable form is specifically used for severe malaria rather than quinine. In adults, it may not be as effective as artesunate. It is given by injection in a muscle. It is also available by mouth in combination with lumefantrine, known as artemether/lumefantrine.

<span class="mw-page-title-main">Artesunate</span> Chemical compound

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

<span class="mw-page-title-main">Dihydroartemisinin</span> Drug used to treat malaria

Dihydroartemisinin is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs. It is sold commercially in combination with piperaquine and has been shown to be equivalent to artemether/lumefantrine.

<span class="mw-page-title-main">Amodiaquine</span> Chemical compound

Amodiaquine (ADQ) is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. It is recommended to be given with artesunate to reduce the risk of resistance. Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria. Though, the WHO in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.

<span class="mw-page-title-main">Piperaquine</span> Chemical compound

Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine. Due to widespread parasite resistance to piperaquine, the drug fell out of use as a monotherapy, and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the detoxification of host heme.

Frederick Wabwire-Mangen is a Ugandan physician, public health specialist and medical researcher. Currently he is Professor of Epidemiology and Head of Department of Epidemiology & Biostatistics at Makerere University School of Public Health. Wabwire-Mangen also serves as the Chairman of Council of Kampala International University and a founding member of Accordia Global Health Foundation’s Academic Alliance

<span class="mw-page-title-main">Arterolane</span> Chemical compound

Arterolane, also known as OZ277 or RBx 11160, is a substance that was tested for antimalarial activity by Ranbaxy Laboratories. It was discovered by US and European scientists who were coordinated by the Medicines for Malaria Venture (MMV). Its molecular structure is uncommon for pharmacological compounds in that it has both an ozonide (trioxolane) group and an adamantane substituent.

Pregnancy-associated malaria (PAM) or placental malaria is a presentation of the common illness that is particularly life-threatening to both mother and developing fetus. PAM is caused primarily by infection with Plasmodium falciparum, the most dangerous of the four species of malaria-causing parasites that infect humans. During pregnancy, a woman faces a much higher risk of contracting malaria and of associated complications. Prevention and treatment of malaria are essential components of prenatal care in areas where the parasite is endemic – tropical and subtropical geographic areas. Placental malaria has also been demonstrated to occur in animal models, including in rodent and non-human primate models.

The Infectious Diseases Institute (IDI), established within Makerere University, is a Ugandan not-for-profit organization which aims to strengthen health systems in Africa, with a strong emphasis on infectious diseases; through research and capacity development. In pursuit of its mission both in Uganda and Sub-Saharan Africa, IDI provides care to People Living with HIV (PLHIV) and other infectious diseases, builds capacity among healthcare workers through training and ongoing support, maintains a focus on prevention, and carries out relevant research.

Harriet Mayanja-Kizza, MBChB, MMed, MSc, FACP, is a Ugandan physician, researcher, and academic administrator. She is the former Dean of Makerere University School of Medicine, the oldest medical school in East Africa, established in 1924.

<span class="mw-page-title-main">Elioda Tumwesigye</span> Ugandan politician

Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.

Rhoda Wanyenze is a physician, public health consultant, academic and medical administrator, who serves as the Dean of Makerere University School of Public Health, a component school of Makerere University College of Health Sciences, which is part of Makerere University, Uganda's oldest and largest public university.

Professor Paul Waako, is a Ugandan pharmacologist, academic and academic administrator, who serves as the Vice Chancellor of Busitema University, a public university in the Eastern Region of Uganda, since 1 May 2019.

<span class="mw-page-title-main">Andrew Kambugu</span> Ugandan physician

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.

Damalie Nakanjako, is a Ugandan specialist physician, internist, immunologist, infectious diseases consultant, academic and researcher, who serves as the Principal and Professor of Medicine at Makerere University College of Health Sciences. Immediately prior to her present position, she served as Dean of Makerere University School of Medicine, from 2019 until 17 February 2021.

David A. Fidock, is the CS Hamish Young Professor of Microbiology and Immunology and Professor of Medical Sciences at Columbia University Irving Medical Center in Manhattan.

References

  1. 1 2 3 4 "Professor Moses Kamya, MBChB, MMed, MPH, PhD: Professor and Chair, Department Medicine, Makerere University". Kampala: Makerere University-UCSF Research Collaboration. 21 October 2017. Retrieved 21 October 2017.
  2. 1 2 3 IDI (15 March 2017). "Infectious Diseases Institute: Moses R. Kamya". Kampala: Makerere University Infectious Diseases Institute (IDI). Archived from the original on 21 October 2017. Retrieved 21 October 2017.
  3. ↑ Kambugu, Andrew (2008). "Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy". Clinical Infectious Diseases. 46 (11): 1694–1701. doi:10.1086/587667. PMC   2593910 . PMID   18433339.
  4. ↑ Meya, David B. (2010). "Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings". Clinical Infectious Diseases. 51 (4): 448–455. doi:10.1086/655143. PMC   2946373 . PMID   20597693.
  5. ↑ Havlir, Diane V.; Balzer, Laura B.; Charlebois, Edwin D.; Clark, Tamara D.; Kwarisiima, Dalsone; Ayieko, James; Kabami, Jane; Sang, Norton; Liegler, Teri; Chamie, Gabriel; Camlin, Carol S.; Jain, Vivek; Kadede, Kevin; Atukunda, Mucunguzi; Ruel, Theodore (2019-07-18). "HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa". New England Journal of Medicine. 381 (3): 219–229. doi:10.1056/NEJMoa1809866. ISSN   0028-4793. PMC   6748325 . PMID   31314966.
  6. ↑ Kamya, Moses R; Mayanja-Kizza, Harriet; Kambugu, Andrew; Bakeera-Kitaka, Sabrina; Semitala, Fred; Mwebaze-Songa, Patricia; Castelnuovo, Barbara; Schaefer, Petra; Spacek, Lisa A; Gasasira, Anne F; Katabira, Elly; Colebunders, Robert; Quinn, Thomas C; Ronald, Allan; Thomas, David L (2007-10-01). "Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy". Journal of Acquired Immune Deficiency Syndromes. 46 (2): 187–193. doi: 10.1097/QAI.0b013e31814278c0 . ISSN   1525-4135. PMID   17693883. S2CID   41634539.
  7. ↑ Yeka, Adoke; Gasasira, Anne; Mpimbaza, Arthur; Achan, Jane; Nankabirwa, Joaniter; Nsobya, Sam; Staedke, Sarah G.; Donnelly, Martin J.; Wabwire-Mangen, Fred; Talisuna, Ambrose; Dorsey, Grant; Kamya, Moses R.; Rosenthal, Philip J. (2012-03-01). "Malaria in Uganda: Challenges to control on the long road to elimination: I. Epidemiology and current control efforts". Acta Tropica. Tackling The Malaria "End Game": Regional Needs And Challenges For Successful Malaria Elimination. 121 (3): 184–195. doi:10.1016/j.actatropica.2011.03.004. ISSN   0001-706X. PMC   3156969 . PMID   21420377.
  8. ↑ Kakuru, Abel; Jagannathan, Prasanna; Muhindo, Mary K.; Natureeba, Paul; Awori, Patricia; Nakalembe, Miriam; Opira, Bishop; Olwoch, Peter; Ategeka, John; Nayebare, Patience; Clark, Tamara D.; Feeney, Margaret E.; Charlebois, Edwin D.; Rizzuto, Gabrielle; Muehlenbachs, Atis (2016-03-10). "Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy". New England Journal of Medicine. 374 (10): 928–939. doi:10.1056/NEJMoa1509150. ISSN   0028-4793. PMC   4847718 . PMID   26962728.
  9. ↑ Kilama, Maxwell; Smith, David L.; Hutchinson, Robert; Kigozi, Ruth; Yeka, Adoke; Lavoy, Geoff; Kamya, Moses R.; Staedke, Sarah G.; Donnelly, Martin J.; Drakeley, Chris; Greenhouse, Bryan; Dorsey, Grant; Lindsay, Steve W. (2014-03-21). "Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda". Malaria Journal. 13 (1): 111. doi: 10.1186/1475-2875-13-111 . ISSN   1475-2875. PMC   4001112 . PMID   24656206.
  10. ↑ Asua, Victor (2020). "Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda". The Journal of Infectious Diseases. pp. 985–994. doi:10.1093/infdis/jiaa687. PMC   8006419 . PMID   33146722 . Retrieved 2023-02-03.
  11. ↑ Helb, Danica A.; Tetteh, Kevin K. A.; Felgner, Philip L.; Skinner, Jeff; Hubbard, Alan; Arinaitwe, Emmanuel; Mayanja-Kizza, Harriet; Ssewanyana, Isaac; Kamya, Moses R.; Beeson, James G.; Tappero, Jordan; Smith, David L.; Crompton, Peter D.; Rosenthal, Philip J.; Dorsey, Grant (2015-08-11). "Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities". Proceedings of the National Academy of Sciences. 112 (32): E4438-47. Bibcode:2015PNAS..112E4438H. doi: 10.1073/pnas.1501705112 . ISSN   0027-8424. PMC   4538641 . PMID   26216993.
  12. ↑ Tamara, D. Clark (2008). "Factors Determining the Heterogeneity of Malaria Incidence in Children in Kampala, Uganda". The Journal of Infectious Diseases. 198 (3): 393–400. doi: 10.1086/589778 . PMID   18522503. S2CID   13085319.
  13. ↑ Kamya, Moses R.; Yeka, Adoke; Bukirwa, Hasifa; Lugemwa, Myers; Rwakimari, John B.; Staedke, Sarah G.; Talisuna, Ambrose O.; Greenhouse, Bryan; Nosten, François; Rosenthal, Philip J.; Wabwire-Mangen, Fred; Dorsey, Grant (2007-05-18). "Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial". PLOS Clinical Trials. 2 (5): e20. doi: 10.1371/journal.pctr.0020020 . ISSN   1555-5887. PMC   1876597 . PMID   17525792.
  14. ↑ Rosenthal, Philip J.; Breman, Joel G.; Djimde, Abdoulaye A.; John, Chandy C.; Kamya, Moses R.; Leke, Rose G. F.; Moeti, Matshidiso R.; Nkengasong, John; Bausch, Daniel G. (2020-06-03). "COVID-19: Shining the Light on Africa". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1145–1148. doi:10.4269/ajtmh.20-0380. ISSN   0002-9637. PMC   7253089 . PMID   32372749.
  15. ↑ Andolina, Chiara; Rek, John C; Briggs, Jessica; Okoth, Joseph; Musiime, Alex; Ramjith, Jordache; Teyssier, Noam; Conrad, Melissa; Nankabirwa, Joaniter I; Lanke, Kjerstin; Rodriguez-Barraquer, Isabel; Meerstein-Kessel, Lisette; Arinaitwe, Emmanuel; Olwoch, Peter; Rosenthal, Philip J (2021-11-01). "Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study". The Lancet Infectious Diseases. 21 (11): 1568–1578. doi:10.1016/S1473-3099(21)00072-4. ISSN   1473-3099. PMC   8554388 . PMID   34146476.
  16. ↑ Kilama, Maxwell; Lindsay, Steve W.; Greenhouse, Bryan; Arinaitwe, Emmanuel; Kamya, Moses R.; Staedke, Sarah G.; Katureebe, Agaba; Wanzira, Humphrey; Rosenthal, Philip J.; Kigozi, Simon P.; Drakeley, Chris; Smith, David L.; Tatem, Andrew J.; Barusya, Chris; Dorsey, Grant (2015-05-06). "Malaria Transmission, Infection, and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control". The American Journal of Tropical Medicine and Hygiene. 92 (5): 903–912. doi:10.4269/ajtmh.14-0312. ISSN   0002-9637. PMC   4426576 . PMID   25778501.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.